Compare Stocks

Date Range: 

 TeleflexInsuletAbiomedFresenius SE & Co. KGaANovoCure
SymbolNYSE:TFXNASDAQ:PODDNASDAQ:ABMDOTCMKTS:FSNUYNASDAQ:NVCR
Price Information
Current Price$407.64$226.75$282.72$13.15$182.01
52 Week RangeBuyHoldHoldBuyHold
MarketRank™
Overall Score2.01.61.61.41.6
Analysis Score2.63.22.10.02.2
Community Score2.32.72.62.32.5
Dividend Score1.70.00.01.70.0
Ownership Score1.70.01.70.01.7
Earnings & Valuation Score1.91.91.93.11.9
Analyst Ratings
Consensus RecommendationBuyHoldHoldBuyHold
Consensus Price Target$460.44$263.85$348.33N/A$195.71
% Upside from Price Target12.95% upside16.36% upside23.21% upsideN/A7.53% upside
Trade Information
Market Cap$19.05 billion$15.51 billion$13.43 billion$28.15 billion$19.90 billion
Beta1.140.761.411.361.29
Average Volume202,938489,548313,14131,112963,017
Sales & Book Value
Annual Revenue$2.60 billion$738.20 million$840.88 million$39.66 billion$351.32 million
Price / Sales7.3420.3415.210.7453.58
Cashflow$16.46 per share$0.54 per share$4.52 per share$2.43 per shareN/A
Price / Cash24.77423.2062.525.40N/A
Book Value$64.35 per share$1.23 per share$23.64 per share$13.38 per share$2.20 per share
Price / Book6.33184.3511.960.9882.73
Profitability
Net Income$461.47 million$11.60 million$203.01 million$2.11 billion$-7,230,000.00
EPS$11.15$0.19$4.74$0.94($0.07)
Trailing P/E Ratio52.46515.3562.1414.45958.00
Forward P/E Ratio32.30206.1458.0512.64423.28
P/E Growth2.63N/A4.15N/AN/A
Net Margins14.66%3.33%25.89%4.99%4.26%
Return on Equity (ROE)16.33%8.94%15.34%6.74%7.40%
Return on Assets (ROA)7.66%2.07%13.51%2.63%3.94%
Dividend
Annual Payout$1.36N/AN/A$0.17N/A
Dividend Yield0.33%N/AN/A1.29%N/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout Ratio12.20%N/AN/A18.09%N/A
Years of Consecutive Dividend Growth1 YearsN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.63%1.55%N/A0.68%N/A
Current Ratio2.99%6.62%6.81%1.21%4.02%
Quick Ratio1.88%5.91%6.02%0.92%3.74%
Ownership Information
Institutional Ownership Percentage89.78%N/A93.95%0.06%71.09%
Insider Ownership Percentage2.21%1.10%3.40%N/A5.07%
Miscellaneous
Employees14,0001,9001,536311,2691,023
Shares Outstanding46.73 million66.21 million45.23 million2.23 billion103.41 million
Next Earnings Date7/29/2021 (Estimated)8/5/2021 (Estimated)8/5/2021 (Estimated)7/29/2021 (Estimated)7/29/2021 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Why buying the NovoCure Limited (NASDAQ:NVCR) Stock Today Might Make SenseWhy buying the NovoCure Limited (NASDAQ:NVCR) Stock Today Might Make Sense
stocksregister.com - May 8 at 3:04 PM
Insider Selling: NovoCure Limited (NASDAQ:NVCR) Director Sells 1,000 Shares of StockInsider Selling: NovoCure Limited (NASDAQ:NVCR) Director Sells 1,000 Shares of Stock
americanbankingnews.com - May 6 at 6:00 PM
NovoCure Limited (NASDAQ:NVCR) Insider Pritesh Shah Sells 1,290 SharesNovoCure Limited (NASDAQ:NVCR) Insider Pritesh Shah Sells 1,290 Shares
americanbankingnews.com - May 6 at 6:00 PM
Q2 2021 Earnings Estimate for NovoCure Limited (NASDAQ:NVCR) Issued By Truist SecuritiQ2 2021 Earnings Estimate for NovoCure Limited (NASDAQ:NVCR) Issued By Truist Securiti
americanbankingnews.com - May 3 at 2:00 AM
NovoCure Limited (NASDAQ:NVCR) Expected to Earn Q2 2021 Earnings of $0.04 Per ShareNovoCure Limited (NASDAQ:NVCR) Expected to Earn Q2 2021 Earnings of $0.04 Per Share
americanbankingnews.com - May 3 at 2:00 AM
NovoCure (NASDAQ:NVCR) Announces Quarterly  Earnings ResultsNovoCure (NASDAQ:NVCR) Announces Quarterly Earnings Results
americanbankingnews.com - May 1 at 5:14 PM
Earnings Miss: NovoCure Limited Missed EPS And Analysts Are Revising Their Forecasts - NasdaqEarnings Miss: NovoCure Limited Missed EPS And Analysts Are Revising Their Forecasts - Nasdaq
nasdaq.com - May 1 at 12:54 PM
Is Novocure Stock Overvalued? - Motley FoolIs Novocure Stock Overvalued? - Motley Fool
fool.com - April 30 at 11:52 AM
Is Novocure Stock Overvalued?Is Novocure Stock Overvalued?
finance.yahoo.com - April 30 at 11:51 AM
Recap: NovoCure Q1 Earnings - BenzingaRecap: NovoCure Q1 Earnings - Benzinga
benzinga.com - April 29 at 11:12 PM
NovoCure (NVCR) Q1 2021 Earnings Call Transcript - Motley FoolNovoCure (NVCR) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - April 29 at 11:12 PM
Can You Get A Quick Recovery From NovoCure Limited (NASDAQ:NVCR) Given A -3.44% Drop From High?Can You Get A Quick Recovery From NovoCure Limited (NASDAQ:NVCR) Given A -3.44% Drop From High?
marketingsentinel.com - April 29 at 6:11 PM
NovoCure (NASDAQ:NVCR) Shares Gap Down to $205.50NovoCure (NASDAQ:NVCR) Shares Gap Down to $205.50
americanbankingnews.com - April 29 at 1:52 PM
NovoCure EPS misses by $0.06, misses on revenue - Seeking AlphaNovoCure EPS misses by $0.06, misses on revenue - Seeking Alpha
seekingalpha.com - April 29 at 1:10 PM
NVCR Stock Dives On Surprise Loss As Revenue Also Falls Short - Investors Business DailyNVCR Stock Dives On Surprise Loss As Revenue Also Falls Short - Investor's Business Daily
investors.com - April 29 at 1:10 PM
NovoCure: Q1 Earnings Snapshot - Greenwich TimeNovoCure: Q1 Earnings Snapshot - Greenwich Time
greenwichtime.com - April 29 at 1:10 PM
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update - Business WireNovocure Reports First Quarter 2021 Financial Results and Provides Company Update - Business Wire
businesswire.com - April 29 at 1:10 PM
Novocure Stock Skids On Surprise Loss As Revenue Also Falls ShortNovocure Stock Skids On Surprise Loss As Revenue Also Falls Short
finance.yahoo.com - April 29 at 1:10 PM
NovoCure Limited 2021 Q1 - Results - Earnings Call PresentationNovoCure Limited 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - April 29 at 10:24 AM
NovoCure: Q1 Earnings SnapshotNovoCure: Q1 Earnings Snapshot
apnews.com - April 29 at 8:10 AM
Do Its Financials Have Any Role To Play In Driving NovoCure Limiteds (NASDAQ:NVCR) Stock Up Recently?Do Its Financials Have Any Role To Play In Driving NovoCure Limited's (NASDAQ:NVCR) Stock Up Recently?
nasdaq.com - April 29 at 8:10 AM
Novocure Reports First Quarter 2021 Financial Results and Provides Company UpdateNovocure Reports First Quarter 2021 Financial Results and Provides Company Update
finance.yahoo.com - April 29 at 8:10 AM
Novocure Reports Surprise Loss As Revenue Falls ShortNovocure Reports Surprise Loss As Revenue Falls Short
finance.yahoo.com - April 29 at 8:10 AM
Why NovoCure (NVCR) Might Surprise This Earnings Season - Yahoo FinanceWhy NovoCure (NVCR) Might Surprise This Earnings Season - Yahoo Finance
finance.yahoo.com - April 28 at 10:04 AM
Why NovoCure (NVCR) Might Surprise This Earnings SeasonWhy NovoCure (NVCR) Might Surprise This Earnings Season
finance.yahoo.com - April 28 at 10:04 AM
NovoCure (NASDAQ:NVCR) Stock Rating Upgraded by Zacks Investment ResearchNovoCure (NASDAQ:NVCR) Stock Rating Upgraded by Zacks Investment Research
marketbeat.com - April 28 at 4:31 AM
DateCompanyBrokerageAction
5/6/2021TeleflexMorgan StanleyBoost Price Target
5/6/2021TeleflexSVB LeerinkBoost Price Target
3/18/2021TeleflexRaymond JamesBoost Price Target
2/25/2021TeleflexPiper SandlerReiterated Rating
1/27/2021TeleflexJMP SecuritiesBoost Price Target
1/11/2021TeleflexWells Fargo & CompanyBoost Price Target
1/8/2021TeleflexKeyCorpBoost Price Target
1/6/2021TeleflexNeedham & Company LLCBoost Price Target
12/15/2020TeleflexUBS GroupBoost Price Target
5/7/2021InsuletBTIG ResearchReiterated Rating
3/25/2021InsuletCanaccord GenuityUpgrade
3/3/2021InsuletOppenheimerBoost Price Target
12/16/2020InsuletSmith Barney CitigroupDowngrade
12/16/2020InsuletCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
7/13/2020AbiomedOTR GlobalUpgrade
3/23/2020AbiomedStephensLower Price Target
9/30/2019AbiomedWilliam BlairReiterated Rating
8/2/2019AbiomedGuggenheimDowngrade
4/28/2021Fresenius SE & Co. KGaABarclaysReiterated Rating
2/19/2021Fresenius SE & Co. KGaABerenberg BankReiterated Rating
2/10/2021Fresenius SE & Co. KGaAJPMorgan Chase & Co.Reiterated Rating
2/4/2021Fresenius SE & Co. KGaADeutsche Bank AktiengesellschaftDowngrade
2/3/2021Fresenius SE & Co. KGaADZ BankReiterated Rating
1/6/2021Fresenius SE & Co. KGaANord/LBReiterated Rating
12/3/2020Fresenius SE & Co. KGaABank of AmericaDowngrade
8/5/2020Fresenius SE & Co. KGaAJefferies Financial GroupDowngrade
3/24/2020Fresenius SE & Co. KGaASanford C. BernsteinUpgrade
3/22/2019Fresenius SE & Co. KGaAThe Goldman Sachs GroupReiterated Rating
4/26/2021NovoCureTruist SecuritiesBoost Price Target
4/20/2021NovoCureWedbushReiterated Rating
4/20/2021NovoCureMizuhoBoost Price Target
4/20/2021NovoCureNorthland SecuritiesBoost Price Target
8/3/2020NovoCureSunTrust BanksReiterated Rating
(Data available from 5/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.